

## 2025 Drug Analysis (Synthetic Drug) Proficiency Test FTS-25-DRUG1 Summary Report

**The Submission Deadline for this test was July 25, 2025**

*The test was manufactured by FTS at the FTS Laboratory Facility (127 W. Grand River Avenue, Williamston, MI 48895) and all activities were coordinated by Rebecca Smith (rsmith@forsci.com), Proficiency Test Program Manager. Ms. Smith is also authorizing the release of this report. This is the summary report issued on 8/12/25. FTS considers all reports confidential and does not release information regarding participant's results without authorization from that participant.*

### **Summary**

Test results were received in 32 of 34 tests distributed (94% response rate). Of the 32 respondents:

#### Item 1 (Peppermint Leaves with ADB-Fubinaca)

29 of 32 (91%) reported that Item 1 contained ADB-Fubinaca (N-(1-(aminocarbonyl)-2,2-dimethylpropyl)-1-((4-fluorophenyl)methyl)-1H-indazole-3-carboxamide).

1 of 32 (3%) also reported that Item 1 contained ADB-INACA.

1 of 32 (3%) also reported that Item 1 contained Menthol.

3 of 32 (9%) reported that Item 1 contained no controlled substances/Levomenthol.

#### Item 2 (Peppermint Leaves)

31 of 32 (97%) reported that Item 2 contained no controlled substances/Levomenthol/Menthol.

1 of 32 (3%) reported that Item 2 contained ADB-Fubinaca (N-(1-(aminocarbonyl)-2,2-dimethylpropyl)-1-((4-fluorophenyl)methyl)-1H-indazole-3-carboxamide).

### **Manufacturer's Information**

All items were packaged at separate times. The area was cleaned and the item was stored before another item was produced.

Item 1 was produced by weighing ~15 grams of peppermint leaves (Frontier Coop #6305352) using a calibrated Mettler PB1502 balance and transferred into a Pyrex dish. 0.15 gram of ADB-Fubinaca (Guangdong Biological Chemistry Ltd, China) was dissolved in 100mL acetone (Alfa Aesar Lot# M27C751, Item 43053-4L) in an Erlenmeyer flask. The ADB-Fubinaca/acetone mixture was added to the plant material until the leaves were covered. The leaves/acetone/ADB-Fubinaca mixture was stirred several times and allowed to evaporate in the fume hood at room temperature. ~0.3 gram of the plant material was packaged in a wax envelope and further packaged into a labeled glassine envelope. The item was further heatsealed in an AMPAC envelope, sealed and labeled per FTS guidelines.

Item 2 was produced by weighing ~15 grams of peppermint leaves (Frontier Coop #6305352) using a calibrated Mettler PB1502 balance and transferred into a large beaker. 100mL acetone (Alfa Aesar Lot# M27C751, Item 43053-4L) was added until the leaves were covered. The leaves/acetone mixture was

stirred several times and allowed to evaporate in the fume hood at room temperature. ~0.3 gram of the plant material was packaged in a wax envelope and further packaged into a labeled glassine envelope. The item was further heatsealed in an AMPAC envelope, sealed and labeled per FTS guidelines.

Both items with matching UTICs were packaged together in a 6" x 9" manila envelope, sealed and labeled per FTS guidelines.

#### Assigned Value

Proficiency tests under ISO 17043:2023 are assessed via comparison of the participant result to the assigned value of a proficiency test item or items. For quantitative tests, FTS determines the assigned value based on statistical methods described in ISO 13528:2022. For qualitative tests, the FTS study coordinator determines the assigned value based on a number of factors, including product source information, internal and/or external pre-distribution laboratory analysis, and consensus of responses (consensus value).

Quality systems and laboratory reporting guidelines vary greatly from laboratory to laboratory, therefore participating laboratories and their accrediting bodies are responsible for the assessment of whether a reported result is an outlying result.

For this proficiency test, the following assigned values are based on source information which was then confirmed by laboratory analysis:

Item 1: ADB-Fubinaca

Item 2: No controlled substances

Please examine the questioned items to identify any controlled substance(s) present.

#### Items Submitted

**Item 1:** Sample of questioned material.

**Item 2:** Sample of questioned material.

3) Indicate all methods used for analysis (select all that apply):

- A)  Macro/Microscopic Examinations
- B)  Chemical Spot Tests
- C)  GC/FID/TEA/ECD
- D)  GC/MS
- E)  Micro-crystal Tests

- F)  SEM/EDS
- G)  Thin Layer Chromatography
- H)  PLM
- I)  HPLC
- J)  IR/FTIR Analysis
- K)  ICP-MS
- L)  CE
- M)  HPLC/MS
- N)  DART TOF-MS
- O)  Raman Spectroscopy

UTIC	Webcode	Indicate all methods used for analysis (select all that apply):
p2025301	W182	GC/MS
p2025302	W022	GC/MS; Macro/Microscopic Examinations
p2025303	W061	GC/MS; HPLC/MS
p2025304	W061	GC/MS
p2025305	W061	GC/MS; HPLC/MS
p2025306	W061	GC/MS
p2025307	W061	Chemical Spot Tests; GC/MS
p2025308	W144	Macro/Microscopic Examinations; Chemical Spot Tests
p2025309	W193	Macro/Microscopic Examinations; GC/MS
p2025310	W163	GC/MS
p2025311	W163	GC/MS
p2025312	W163	Macro/Microscopic Examinations; Chemical Spot Tests; GC/MS
p2025313	W163	GC/MS
p2025314	W132	Macro/Microscopic Examinations; GC/MS; Thin Layer Chromatography
p2025315	W261	GC/MS
p2025316	W261	GC/MS
p2025317	W261	GC/MS
p2025318	W261	GC/MS; IR/FTIR Analysis; Raman Spectroscopy
p2025319	W092	IR/FTIR Analysis; Macro/Microscopic Examinations; GC/MS; HPLC; GC/FID/TEA/ECD
p2025320	W244	Macro/Microscopic Examinations; Chemical Spot Tests; GC/MS
p2025321	W034	Macro/Microscopic Examinations; GC/FID/TEA/ECD; GC/MS
p2025322	W264	GC/MS; HPLC/MS
p2025323	W030	GC/MS; Macro/Microscopic Examinations
p2025325	W015	Macro/Microscopic Examinations; GC/MS

UTIC	Webcode	Indicate all methods used for analysis (select all that apply):
p2025326	W015	Macro/Microscopic Examinations; GC/MS
p2025327	W015	GC/MS; IR/FTIR Analysis; Macro/Microscopic Examinations
p2025328	W013	Macro/Microscopic Examinations; Chemical Spot Tests; GC/MS
p2025329	W051	GC/MS; HPLC; Macro/Microscopic Examinations
p2025330	W214	Macro/Microscopic Examinations; GC/MS; IR/FTIR Analysis
p2025332	W098	GC/MS
p2025333	W004	Macro/Microscopic Examinations; GC/MS; DART TOF-MS; GC/FID/TEA/ECD
p2025334	W004	Macro/Microscopic Examinations; GC/FID/TEA/ECD; GC/MS; DART TOF-MS

4) Other methods used (if none, please enter "N/A"):

UTIC	Webcode	Other methods used
p2025320	W244	GC-MS Headspace SDME
p2025325	W015	GC Retention time
p2025326	W015	Chromatographic Retention Time
p2025327	W015	color test, GC retention time
p2025333	W004	weight measurement

5) Item 1

What controlled substance(s) or controlled substance analog(s) (i.e. drugs), if any, were identified in the questioned material from Item 1? Note: Please answer this question regardless of the legal status of the substance in your jurisdiction.

UTIC	Webcode	Item 1
		What controlled substance(s) or controlled substance analog(s) (i.e. drugs), if any, were identified in the questioned material from Item 1?
p2025301	W182	ADB-FUBINACA
p2025302	W022	ADB-FUBINACA
p2025303	W061	ADB-FUBINACA
p2025304	W061	ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)
p2025305	W061	N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (ADB FUBINACA)
p2025306	W061	ADB-FUBINACA
p2025307	W061	ADB-FUBINACA indicated. It also contains menthol.

UTIC	Webcode	Item 1  What controlled substance(s) or controlled substance analog(s) (i.e. drugs), if any, were identified in the questioned material from Item 1?
p2025308	W144	No controlled substances were found.
p2025309	W193	ADB-FUBINACA
p2025310	W163	N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA)
p2025311	W163	N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA) was detected in this item.
p2025312	W163	N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA)
p2025313	W163	The results for the substance in ITEM 1 came back as negative.
p2025314	W132	ADB-FUBINACA
p2025315	W261	ADB-Fubinaca and Menthol
p2025316	W261	ADB-Fubinaca and Menthol
p2025317	W261	ADB-Fubinaca and Menthol
p2025318	W261	ADB-Fubinaca and Menthol
p2025319	W092	ADB-FUBINACA was identified in the questioned material from item 1.
p2025320	W244	No controlled substance or controlled substance analog was identified. Levomenthol was detected in Item #1.
p2025321	W034	ADB-FUBINACA ADB-INACA [Not Confirmed]
p2025322	W264	ADB-FUBINACA
p2025323	W030	ADB-FUBINACA
p2025325	W015	ADB-FUBINACA
p2025326	W015	ADB-FUBINACA
p2025327	W015	ADB-FUBINACA
p2025328	W013	ADB-FUBINACA
p2025329	W051	ADB-FUBINACA
p2025330	W214	ADB-FUBINACA
p2025332	W098	ADB-FUBINACA
p2025333	W004	ADB-FUBINACA
p2025334	W004	ADB-FUBINACA

6) **Item 2**

What controlled substance(s) or controlled substance analog(s) (i.e. drugs), if any, were identified in the questioned material from Item 2? Note: Please answer this question regardless of the legal status of the substance in your jurisdiction.

UTIC	Webcode	Item 2 What controlled substance(s) or controlled substance analog(s) (i.e. drugs), if any, were identified in the questioned material from Item 2?
p2025301	W182	none
p2025302	W022	no controlled substance identified
p2025303	W061	Common illicit drugs were not detected.
p2025304	W061	No prohibited drug found
p2025305	W061	No drugs detected
p2025306	W061	No controlled substances detected
p2025307	W061	No prohibited substance detected.
p2025308	W144	No controlled substances were found.
p2025309	W193	No controlled substance or controlled substance analog identified.
p2025310	W163	NEGATIVE
p2025311	W163	No controlled substances were detected in this item.
p2025312	W163	• No Controlled Substances Identified
p2025313	W163	The drug that was identified in the substance in ITEM 2 was N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA).
p2025314	W132	No controlled drug detected.
p2025315	W261	Menthol (not control)
p2025316	W261	Menthol (not control)
p2025317	W261	Menthol (not control)
p2025318	W261	Menthol
p2025319	W092	No controlled substance(s) or controlled substance analog(s) (i.e. drugs) were identified in the questioned material from item 2.
p2025320	W244	No controlled substance or controlled substance analog was identified. Levomenthol was detected in Item #2.
p2025321	W034	NA
p2025322	W264	Nil
p2025323	W030	No controlled substances
p2025325	W015	None
p2025326	W015	No controlled substances identified (or analogs)
p2025327	W015	no controlled drugs
p2025328	W013	No Controlled Substance Detected
p2025329	W051	No controlled substance identified

UTIC	Webcode	Item 2 What controlled substance(s) or controlled substance analog(s) (i.e. drugs), if any, were identified in the questioned material from Item 2?
p2025330	W214	No controlled substances detected
p2025332	W098	No controlled substances
p2025333	W004	No controlled substances found.
p2025334	W004	No controlled substances found.

7) How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court). In order to maintain confidentiality, please refrain from including identifying information specific to your laboratory.

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).
p2025301	W182	The plant material in Items 1 and 2 were analyzed by gas-chromatography/mass spectrometry (GC-MS). Item 1 contained ADB-FUBINACA, a Schedule I controlled substance. Item 2 did not contain any controlled substances.
p2025302	W022	Lab item #1.1: Green vegetation from an envelope labeled to contain item 1, 0.30 grams net +/- 0.02 grams Confirmed N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA), an indazole-3-carboxamide.  Lab item #1.2: Green vegetation from an envelope labeled to contain item 2, 0.30 grams net +/- 0.02 grams No controlled substances were identified.
p2025303	W061	N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA) was identified as a component of the plant material (Item 1).  COMMON ILLICIT DRUGS were not detected in the plant material (Item 2).

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).
p2025304	W061	<p>Item 1. Item found to contain ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide).</p> <p>i) This substance is not separately specified in Schedule 1 of the [redacted], but is a structural isomer of a prescribed drug by virtue of the prohibited plant or prohibited drug clause (a).</p> <p>ii) The Schedule 1 prescribed drug being “N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA).”.</p> <p>Item 2: No prohibited drug found</p>
p2025305	W061	<p>N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (ADB FUBINACA) detected in item 1.</p> <p>No dangerous drugs detected in item 2.</p>
p2025306	W061	<p>Item 1: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide (which is also known as ADB-FUBINACA) is not explicitly listed in our legislation. However, it is the opinion of our group that ADB-FUBINACA can be classed as an analogue of N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide (which is also known as AB-FUBINACA) through the replacement of the hydrogen on the isopropyl group with a methyl group, to form a tert-butyl group. AB-FUBINACA is explicitly listed in our legislation.</p> <p>Item 2: No controlled substances detected</p>
p2025307	W061	<p>Item 1 - The presence of ADB-FUBINACA is indicated*. It also contains menthol.</p> <p>Item 2 - No prohibited substance detected. It also contains menthol.</p> <p>(included as a footnote after results table) *Identified by comparison to peer reviewed scientific literature.</p>

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).
		<p><b>Item 1</b></p> <p>In the plant material received, the presence of the restricted drugs included in the scope of the approved screening method in the Controlled Substances Section was not identified. (*) (See Note No. 5)</p> <p>(*) Forensic test accredited by ANAB, under ISO/IEC 17025:2017 (the scope can be consulted at the address <a href="http://search.anab.org">http://search.anab.org</a>)</p> <p>Note 5: The Controlled Substances Section reports that the instrumental equipment currently used for the identification of synthetic cannabinoids in plant material is out of service.</p> <p><b>Item 2</b></p> <p>In the plant material received, the presence of Cannabis sativa (*) was not identified. In the plant material, the presence of the restricted drugs included in the scope of the approved screening method in the Controlled Substances Section was not identified either. (*) (See Note No. 5)</p> <p>(*) Forensic test accredited by ANAB, under ISO/IEC 17025:2017 (the scope can be consulted at the address <a href="http://search.anab.org">http://search.anab.org</a>)</p> <p>Note 5: For this plant material with a negative result for Cannabis sativa, it is currently NOT possible to carry out the methodology for screening synthetic cannabinoids, as the equipment in which the methodology was validated is out of service. Once the above is done on the material, if necessary, an extension of the report will be issued.</p>
p2025308	W144	From the analysis, it was found ITEM 1 contained ADB-FUBINACA and no dangerous drugs were detected in ITEM 2.
p2025309	W193	

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).																			
		<ul style="list-style-type: none"> <li>- Item (Unique Reference): ITEM 1</li> <li>- Description on Opening: One heat sealed clear and textured plastic package which contained one white translucent paper envelope labelled 'FTS FORENSIC TESTING SERVICES' which held a green herbal material.</li> <li>- Quantity: 305 milligrams</li> <li>- Drug: N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA)</li> <li>- Legal status: CLASS B</li> </ul> <p style="text-align: center;">//////////</p> <p style="text-align: center;">Item (Unique Reference): ITEM 2</p> <ul style="list-style-type: none"> <li>- Description on Opening: One heat-sealed clear and textured plastic which held a white translucent paper envelope which was labelled 'FTS FORENSIC TESTING SERVICES' which contained a green herbal material.</li> <li>- Quantity: 307 milligrams</li> <li>- Drug: NEGATIVE</li> <li>- Legal status: Not Controlled</li> </ul>																			
p2025310	W163	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center; padding: 2px;">Item</th><th style="text-align: center; padding: 2px;">Description on Opening</th><th style="text-align: center; padding: 2px;">Quantity</th><th style="text-align: center; padding: 2px;">Drug</th><th style="text-align: center; padding: 2px;">Legal Status</th></tr> </thead> <tbody> <tr> <td style="text-align: center; padding: 2px;">FTS-25-DRUG 1</td><td style="padding: 2px;">A) One paper package labelled "FTS-25-DRUG1 Item 1 p2025311" which contained one paper package which contained fragmented leaf material.</td><td style="text-align: center; padding: 2px;">315 milligrams</td><td style="padding: 2px;">N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA)</td><td style="text-align: center; padding: 2px;">Class B</td></tr> <tr> <td style="text-align: center; padding: 2px;">FTS-25-DRUG 1</td><td style="padding: 2px;">B) One paper package labelled "FTS-25-DRUG1 Item 2 p2025311" which contained one paper package which contained fragmented leaf material.</td><td style="text-align: center; padding: 2px;">302 milligrams</td><td style="padding: 2px;">NEGATIVE</td><td style="text-align: center; padding: 2px;">Not Controlled</td></tr> </tbody> </table>					Item	Description on Opening	Quantity	Drug	Legal Status	FTS-25-DRUG 1	A) One paper package labelled "FTS-25-DRUG1 Item 1 p2025311" which contained one paper package which contained fragmented leaf material.	315 milligrams	N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA)	Class B	FTS-25-DRUG 1	B) One paper package labelled "FTS-25-DRUG1 Item 2 p2025311" which contained one paper package which contained fragmented leaf material.	302 milligrams	NEGATIVE	Not Controlled
Item	Description on Opening	Quantity	Drug	Legal Status																	
FTS-25-DRUG 1	A) One paper package labelled "FTS-25-DRUG1 Item 1 p2025311" which contained one paper package which contained fragmented leaf material.	315 milligrams	N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA)	Class B																	
FTS-25-DRUG 1	B) One paper package labelled "FTS-25-DRUG1 Item 2 p2025311" which contained one paper package which contained fragmented leaf material.	302 milligrams	NEGATIVE	Not Controlled																	
p2025311	W163																				

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).
		<p><b><u>Item 1: 306 milligrams of fragmented green herbal material</u></b></p> <p>Drugs Identified:</p> <p>1. N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA) Legal Status: Class B</p> <p>2. Indicated the presence of Menthol, Legal status: Not Controlled</p> <p><b>Legal status refers to the classification of the drug found under the provisions of the [redacted] (as amended).</b></p> <p><b><u>Item 2: 316 milligrams of fragmented green herbal material</u></b></p> <p>Drug Identified:</p> <p>1. No Controlled Drugs Identified, indicated the presence of Menthol Legal Status: Not Controlled</p> <p><b>Legal status refers to the classification of the drug found under the provisions of the [redacted] (as amended).</b></p>
p2025312	W163	<p>I would include how the substance came, describe the appearance of the substance the name of the substance or compound that was detected upon analysis, the legal status, the quantity of the substance present and the purity if appropriate. So in the case of ITEM 1, it was one package, which comprised of folded clear plastic, which contained green herbal material. there was 230 milligrams of it, was reported as negative, deeming it as not controlled under the [redacted] (as amended).</p> <p>In the case of ITEM 2, it was one package, which comprised of folded clear plastic, which contained green herbal material. Upon analysis, the results came back with a synthetic cannabinoid called N-[1-(AMINOCARBONYL)-2,2-DIMETHYLPROPYL]-1-[(4-FLUOROPHENYL)METHYL]-1H-INDAZOLE-3-CARBOXAMIDE (ADB-FUBINACA), which is a Class B drug under the [redacted] (as amended).</p>
p2025313	W163	<p>ADB-FUBINACA is otherwise known as N-(1-amino-3,3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide. N-(1-amino-3,3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide is listed as a controlled drug in the [redacted] (Controlled Drugs) (Declaration) Order 2021 and is therefore a controlled drug under the [redacted]-for item 1.</p>
p2025314	W132	No controlled drug detected for item 2.
p2025315	W261	Item1: contains ADB-Fubinaca a synthetic listed in schedule 7 of the [redacted] Item 2: Menthol(negative) not conclusively identified

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).
p2025316	W261	Item1: contains ADB-Fubinaca a synthetic listed ib schedule 7 of the [redacted] Item 2: Menthol(negative) inconclusively identified
p2025317	W261	ADB-Fubinaca a synthetic listed ib schedule 7 of the [redacted]
p2025318	W261	Item1: contains ADB-Fubinaca a synthetic listed ib schedule 7 of the [redacted] Item 2: Contains a Menthol(negative) is not listed on the schedules of Acts
p2025319	W092	(Item 1): 1 packet (consisting of plastic/paper wrappings) containing 0.31 grammes of a solid containing traces of ADB-FUBINACA <sup>§</sup> . § Controlled under the [redacted] (First Schedule, Part I).  (Item 2): 1 packet (consisting of plastic/paper wrappings) containing 0.29 grammes of a solid in which substances controlled under the [redacted] (Cap. 134) were not detected.
p2025320	W244	No controlled substance or controlled substance analog was identified for Item #1 and Item #2. NOTE: Levomenthol was detected in both Item #1 and Item #2.
p2025321	W034	Item 1 Compartmentalized plastic bag: - Compartment containing (1) white, glassine envelope labeled "FTS FORENSIC TESTING SERVICES; FTS-25-DRUG1; Item 1; p2025321" containing (1) white, glassine envelope containing a green, leafy substance - Compartment containing Item 2 Net Weight: 0.311 +/- 0.060 grams (95.45% Level of Confidence) ADB-FUBINACA ADB-INACA [Not Confirmed]  Item 2 (1) White, glassine envelope labeled "FTS FORENSIC TESTING SERVICES; FTS-25-DRUG1; Item 2; p2025321" containing (1) white, glassine envelope containing a green, leafy substance Net Weight: 0.311 +/- 0.060 grams (95.45% Level of Confidence) No Compounds Confirmed By Standard Procedures One or more compounds were identified, but not confirmed. Examples applicable to this result type may include, but are not limited to: tablet binders, flavoring agents, additives, and botanical or fungal extracts.
p2025322	W264	The exhibits marked "Item 1" and "Item 2" were each found to be vegetative material wrapped in paper. The vegetative material from each paper packaging was analysed and found to contain the following: Item 1: ADB-FUBINACA Item 2: No drugs of concern found

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).									
		<p>Evidence Item 001 (001): One sealed envelope containing one sealed plastic bag containing:..</p> <p>Item # 001-A: One sealed wax paper bag labeled "Item 1" containing one wax paper fold containing green/brown plant material.</p> <p>Item # 001-B: One sealed wax paper bag labeled "Item 2" containing one wax paper fold containing green/brown plant material.</p> <p><b>RESULTS</b></p> <p>Evidence Item # 001-A: One sealed wax paper bag labeled "Item 1" containing one wax paper fold containing green/brown plant material.</p> <p><b>The above item (0.31 grams net weight +/- 0.05 grams at a coverage probability of 99.73%) was found to contain ADB-FUBINACA, Schedule I.</b></p> <p>NOTE: ADB-FUBINACA is a synthetic cannabinoid pharmacophore.</p> <p>Evidence Item # 001-B: One sealed wax paper bag labeled "Item 2" containing one wax paper fold containing green/brown plant material.</p> <p><b>The above item (0.30 grams net weight +/- 0.05 grams at a coverage probability of 99.73%) was found to contain No Detectable Controlled Substance.</b></p>									
p2025323	W030	<p>Items:</p> <p>001-A One (1) piece of wax paper containing vegetative matter (P2025325) 001-B One (1) piece of wax paper containing vegetative matter (P2025325)</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;">Weight</th> <th style="width: 40%;">Substance(s) Identified</th> <th style="width: 20%;"></th> </tr> </thead> <tbody> <tr> <td>001-A 0.315 +/- 0.008* gram</td> <td>ADB-FUBINACA (C)</td> <td>Confirmed</td> </tr> <tr> <td>001-B 0.311 +/- 0.008* gram</td> <td>No controlled substances</td> <td></td> </tr> </tbody> </table> <p>(N) = Narcotic; (C) = Controlled; (Rx) = Prescription; (OTC) = Over-the-counter; (SS) = Structurally similar drug; (U) = Unknown control status; (V) = Veterinary Drug; (N/A) = Not applicable</p> <p>*The expanded uncertainty of the weight is expressed at the 95.45% confidence level.</p>	Weight	Substance(s) Identified		001-A 0.315 +/- 0.008* gram	ADB-FUBINACA (C)	Confirmed	001-B 0.311 +/- 0.008* gram	No controlled substances	
Weight	Substance(s) Identified										
001-A 0.315 +/- 0.008* gram	ADB-FUBINACA (C)	Confirmed									
001-B 0.311 +/- 0.008* gram	No controlled substances										

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).									
p2025326	W015	<p>Items: 001-A One (1) piece of wax paper containing vegetative matter (P2025326) 001-B One (1) piece of wax paper containing vegetative matter (P2025326)</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center; width: 30%;">Weight</th> <th style="text-align: center; width: 40%;">Substance(s) Identified</th> <th style="text-align: center; width: 30%;">Confirmed</th> </tr> </thead> <tbody> <tr> <td>001-A 0.298 +/- 0.008* gram</td> <td>ADB-FUBINACA (C)</td> <td>Confirmed</td> </tr> <tr> <td>001-B 0.306 +/- 0.008* gram</td> <td>No controlled substances</td> <td></td> </tr> </tbody> </table> <p>(N) = Narcotic; (C) = Controlled; (Rx) = Prescription; (OTC) = Over-the-counter; (SS) = Structurally similar drug; (U) = Unknown control status; (V) = Veterinary Drug; (N/A) = Not applicable</p> <p>*The expanded uncertainty of the weight is expressed at the 95.45% confidence level.</p>	Weight	Substance(s) Identified	Confirmed	001-A 0.298 +/- 0.008* gram	ADB-FUBINACA (C)	Confirmed	001-B 0.306 +/- 0.008* gram	No controlled substances	
Weight	Substance(s) Identified	Confirmed									
001-A 0.298 +/- 0.008* gram	ADB-FUBINACA (C)	Confirmed									
001-B 0.306 +/- 0.008* gram	No controlled substances										
p2025327	W015	<p>Items: 001-A One (1) piece of wax paper containing vegetative matter (P2025327) 001-B One (1) piece of wax paper containing vegetative matter (P2025327)</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center; width: 30%;">Weight</th> <th style="text-align: center; width: 40%;">Substance(s) Identified</th> <th style="text-align: center; width: 30%;">Confirmed</th> </tr> </thead> <tbody> <tr> <td>001-A 0.299 +/- 0.008* gram</td> <td>ADB-FUBINACA (C)</td> <td>Confirmed</td> </tr> <tr> <td>001-B 0.305 +/- 0.008* gram</td> <td>No controlled substances</td> <td></td> </tr> </tbody> </table> <p>(N) = Narcotic; (C) = Controlled; (Rx) = Prescription; (OTC) = Over-the-counter; (SS) = Structurally similar drug; (U) = Unknown control status; (V) = Veterinary Drug; (N/A) = Not applicable</p> <p>*The expanded uncertainty of the weight is expressed at the 95.45% confidence level.</p>	Weight	Substance(s) Identified	Confirmed	001-A 0.299 +/- 0.008* gram	ADB-FUBINACA (C)	Confirmed	001-B 0.305 +/- 0.008* gram	No controlled substances	
Weight	Substance(s) Identified	Confirmed									
001-A 0.299 +/- 0.008* gram	ADB-FUBINACA (C)	Confirmed									
001-B 0.305 +/- 0.008* gram	No controlled substances										
p2025328	W013	Item 1 contains ADB-FUBINACA No Controlled Substance Detected for Item 2									
p2025329	W051	Item 1: The exhibit was found to be one (1) packet of fragmented vegetable matter. The fragmented vegetable matter was analysed and found to contain ADB-FUBINACA or its fluoro positional isomer in the phenyl ring. Item 2: The exhibit was found to be one (1) packet of fragmented vegetable matter. The fragmented vegetable matter was analysed and no common controlled drug was detected.									

UTIC	Webcode	How would you state your findings in a report? (Use the same wording as you would to submit a report to the lead investigator and/or court).
p2025330	W214	<p>Item 1 - A white envelope labelled 'FTS-25-DRUG1 Item 1 p2025330' which held a greaseproof paper wrap containing fragmented green vegetable matter Total amount 0.31g Analysis Results ADB-FUBINACA Class B</p> <p>Item 2 - A white envelope labelled 'FTS-25-DRUG1 Item 2 p2025330' which held a greaseproof paper wrap containing fragmented green vegetable matter Total amount 0.30g Analysis Results Unconfirmed Compound</p>
p2025332	W098	<p>Item 1 identified as containing ADB-FUBINACA Item 2 identified as containing non controlled substances</p>
p2025333	W004	<p>Item 1: 0.3049 ± 0.0014 gram of plant material, found to contain ADB-FUBINACA (a Schedule I cannabimimetic agent listed in ... [removed to maintain confidentiality]). Measurement uncertainty of weight measurements is reported at a 95.45% level of confidence.</p> <p>Item 2: No controlled substances found.</p>
p2025334	W004	<p>Item 1 0.7955 gram of plant material including innermost packaging, found to contain ADB-FUBINACA (a Schedule I cannabimimetic agent listed in ...[removed to maintain confidentiality]). [Methods: WM, ME, DART-TOF, GC-MS and GC-FID-MS]</p> <p>Item 2 No controlled substances found. [Methods: WM, ME, DART-TOF, GC-MS and GC-FID-MS]</p> <p>Methods: Weight Measurement (WM), Microscopic Examination (ME), Direct Analysis in Real Time Time-of-Flight Mass Spectrometry (DART-TOF), Gas Chromatography-Flame Ionization Detection-Mass Spectrometry (GC-FID-MS) and Gas Chromatography-Mass Spectrometry (GC-MS).</p>

8) How long did it take to complete this test (in hours)? Please report actual analytical hours only.

9) Did you find this test to be a fair test of the process of the examination and interpretation of synthetic drugs?

A)  Yes

B)  No

UTIC	Webcode	How long did it take to complete this test (in hours)? Please report actual analytical hours only.	Did you find this test to be a fair test of the process of the examination and interpretation of synthetic drugs?
p2025301	W182	4	Yes
p2025302	W022	2 hours	Yes
p2025303	W061	3 hours	Yes
p2025304	W061	8hrs	Yes
p2025305	W061	3	Yes
p2025306	W061	9	Yes
p2025307	W061	12hours	Yes
p2025308	W144	8	Yes
p2025309	W193	3 hours	Yes
p2025310	W163	5 HOURS	Yes
p2025311	W163	3	Yes
p2025312	W163	3	Yes
p2025313	W163	2 hours	Yes
p2025314	W132	8 hours	Yes
p2025315	W261	10 days	Yes
p2025316	W261	72 hrs	Yes
p2025317	W261	32 hrs	Yes
p2025318	W261	160 hrs	No
p2025319	W092	About 48 hours	Yes
p2025320	W244	Ten (10) hours	Yes
p2025321	W034	3 hours	Yes
p2025322	W264	30	Yes
p2025323	W030	3	Yes
p2025325	W015	2	Yes
p2025326	W015	3	Yes
p2025327	W015	2.5	Yes
p2025328	W013	roughly 3 hours	Yes
p2025329	W051	5 hours	Yes
p2025330	W214	1	Yes
p2025332	W098	5	Yes
p2025333	W004	2	Yes
p2025334	W004	approximately 6 hours	Yes

10) How would you change the aspects of the test (i.e. scenario, test samples, question sections, report format) to improve a future version of this test? Comments and suggestions are welcome.

Additionally, this question is a means to provide you with an opportunity to explain or include information about your findings or interpretation, as needed. In order to maintain confidentiality, please refrain from including identifying information specific to your laboratory.

UTIC	Webcode	How would you change the aspects of the test (i.e. scenario, test samples, question sections, report format) to improve a future version of this test? Comments and suggestions are welcome.	FTS Response
p2025313	W163	Including more variety of samples such as a mix of tablets, capsules, powders, mushrooms, edibles on the basis that the reporting officer is signe doff on these competencies.	Thank you for the suggestion!
p2025315	W261	sample was too little( did not make things easy during the analysis)	Thank you for the suggestion. We will consider this for future PTs.
p2025316	W261	I needed more sample and the process was fine.	Please see FTS Response for p2025315.
p2025317	W261	Update Library	